Could Low Doses Acetylsalicylic Acid Prevent Thrombotic Complications in COVID-19 Patients?

Introduction

The recent pandemic Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) may cause some thromboembolic complications ¹ and bilateral interstitial pneumonia (Figure 1), until acute respiratory distress. Alveolar inflammation caused by the hyper-production of pro-inflammatory cytokines (cytokines’ storm) and interleukins triggers thrombosis and increased coagulation. Multisystemic endothelitis associated with microthrombi formation often complicates the Coronavirus Disease-2019 (COVID-19) course and may be responsible for multi-organ dysfunctions, pulmonary embolism (Figure 2), significant injury in the respiratory tract with high mortality rate. ^2,3

OPEN IN VIEWER

Figure 1.

CT showing severe bilateral interstitial pneumonia (“ground glass” opacities) in a patient affected by COVID-19.

OPEN IN VIEWER

Figure 2.

CT of pulmonary thromboembolism (arrow) found in an individual with COVID-19.

Mechanisms of Action of COVID-19

COVID-19 causes an inflammatory state prevalently located in the cells of pulmonary alveoli. In turn, the infection of alveolar, endothelial cells leads to activation and dysfunction of the endothelium. At the beginning coronavirus enters in the cells through ACE2 receptor by the S spike protein. Subsequently, the endothelial dysfunction favors the shift of the hemostatic balance toward the pro-coagulation starting the pro-thrombotic process. ¹⁷ That happens by triggering complex molecular events that leads to inflammation by cytokines’ over-production (cytokine storm). In turn, the condition is responsible for the platelet’s activation, with increased levels of von Willebrand Factor and Factor VIII.

In addition, the increased levels of glycoproteins contribute to thrombin generation and fibrin clot formation. Consequently, an increased thrombotic risk happens, that favors arterial thrombotic events, such as acute myocardial infarction, ischemic stroke and peripheral arterial disease. ³

Anti-Thrombotic ASA Effects

Antithrombotic effect of ASA is due to the inhibition of platelets’ function by acetylation of the COX-1 at the functionally important amino acid serine 529. On the other hand, the COX-1 acetylation inhibits TXA-2, a stimulator of platelet reactivity. ¹⁸ This inhibition results in anti-thrombotic effect, able to prevent thrombosis on the arterial walls. ¹⁹ Most intensively, ASA is employed against arterial thrombosis, while it is not commonly used in venous thrombosis. Nevertheless concerning this topic, some trials (WARFASA, ASPIRE and a recent meta-analysis) evidenced that ASA also reduces venous thrombosis without significantly increasing the risk of bleeding. ^{20 -22} Really, the most common pro-coagulative event happening in COVID-19 is venous thromboembolism (VTE), while arterial thrombosis seems to have a minor incidence. ²³ Some reports also referred on microangiopathies, characterized by microangiopathic hemolytic anemia, thrombocytopenia and organ damage, such as neurological, renal and cardiac dysfunction. ^24,25 It must be also added that pro-coagulation in COVID-19 patients is evidenced by the laboratory findings, showing a thrombocytopenia and an increased D-dimer levels. ²⁶

In Figure 3, the mechanism through COVID-19 induces both arterial and venous thrombi are illustrated.

OPEN IN VIEWER

Figure 3.

Events following the infection with COVID-19. Inhibition of arterial and venous thrombosis induced by low doses ASA.

Conclusive Remarks

Contrarily to the multiple effects (anti-inflammatory, analgesic, anti-pyretic anti-thrombotic and antiviral action against DNA and RNA viruses) obtained with high ASA doses, low doses have antithrombotic and anti-inflammatory effects only. ⁷ Consequently, adult individuals receiving low ASA doses and nowadays affected by SARS-CoV-2, could be protected against possible inflammatory and thrombotic complications. To confirm this hypothesis, a retrospective, observational study performed by the Researches of the Maryland University (US) demonstrated that hospitalized COVID-19 patients who were taking a daily low-dose Aspirin in secondary prevention for CVD had a significantly lower risk of inflammatory and coagulative events compared to those not taking Aspirin. ²⁷ Concerning that, in the near future, the RECOVERY II (Randomized Evaluation of COVID-19 thERapY II) trial will be performed to test the effectiveness of low dose Aspirin as anti-inflammatory and antithrombotic drug in the treatment of patients with COVID-19.

Fruthermore, Hydroxy-Methyl-Glutaryl-Coenzyme A reductases (Statins) are other drugs frequently employed in CVD patients, to reduce dyslipidemia. ²⁸ Nevertheless, they also could supply some beneficial effects against the complications of COVID-19. These favorable effects depend on their pleiotropic actions, such as anti-thrombotic, anti-inflammatory, anti-oxidative effects and improvement of endothelial dysfunction. Moreover, Statins also induce the upregulation of Angiotensin-Converting Enzyme (ACE)-2 receptor, used for cellular entry of the coronavirus. ^29,30 These beneficial results were confirmed by a recent, retrospective study. But in this case, the higher severity of COVID-19 patients due to the CV comorbidities and treated with statin therapy, frustrated the supposed favorable effects. ³¹

Nevertheless, these observations on Aspirin at low doses (with or without Statins) about the favorable effects on the complications of COVID-19 could be confirmed by further studies performed in a wide range.